DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression

Nature Communications

Volumn 6, Issue , 2015, Pages

  Cho, Min Hyung ^a   Park, Ji Hye ^a   Choi, Hee Joo ^a   Park, Mi Kyung ^b   Won, Hee Young ^a   Park, Yeon Ji ^a   Lee, Chang Hoon ^b   Oh, Seung Hyun ^c   Song, Young Soo ^a   Kim, Hyun Sung ^a   Oh, Young Ha ^a   Lee, Jeong Yeon ^a   Kong, Gu ^a  

^a Hanyang University   (South Korea)

^b Dongguk University   (South Korea)

^c Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DISRUPTOR OF TELOMERIC SILENCING 1 LIKE PROTEIN; DNA METHYLTRANSFERASE 1; E1A ASSOCIATED P300 PROTEIN; ESTROGEN RECEPTOR; HISTONE DEACETYLASE 1; HISTONE H3; LYSINE; MYC PROTEIN; NERVE CELL ADHESION MOLECULE; PROGESTERONE RECEPTOR; PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CDH1; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG; UVOMORULIN; DOT1L PROTEIN, HUMAN; EP300 PROTEIN, HUMAN; METHYLTRANSFERASE; MYC PROTEIN, HUMAN;

BLOOD SYSTEM DISORDER; CANCER; GENE EXPRESSION; PHENOTYPE; PROTEIN;

AGGRESSIVENESS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM CELL; BREAST METASTASIS; CANCER GROWTH; CANCER STEM CELL; CANCER SURVIVAL; CELL ACTIVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; EPIGENETIC REPRESSION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PHENOTYPIC VARIATION; PROMOTER REGION; PROTEIN ACETYLATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN METHYLATION; PROTEIN TARGETING; TRANSCRIPTION ELONGATION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BREAST NEOPLASMS; CASE CONTROL STUDY; DISEASE COURSE; GENETIC EPIGENESIS; METABOLISM; METASTASIS; NONOBESE DIABETIC MOUSE; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DISEASE PROGRESSION; E1A-ASSOCIATED P300 PROTEIN; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; METHYLTRANSFERASES; MICE, INBRED NOD; MICE, SCID; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84937837746     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8821     Document Type: Article

References (39)

1. Nguyen, A. T. & Zhang, Y. The diverse functions of Dot1 and H3K79 methylation. Genes Dev. 25, 1345-1358 (2011).
2. Kim, S. K. et al. Human histone H3K79 methyltransferase DOT1L protein [corrected] binds actively transcribing RNA II to regulate gene expression. J. Biol. Chem. 287, 39698-39709 (2012).
3. Ng, H. H., Xu, R. M., Zhang, Y. & Struhl, K. Ubiquitination of histone H2B by Rad6 is required for efficient Dot1-mediated methylation of histone H3 lysine 79. J. Biol. Chem. 277, 34655-34657 (2002).
4. Kim, W., Kim, R., Park, G., Park, J. W. & Kim, J. E. Deficiency of H3K79 histone methyltransferase Dot1-like protein (DOT1L) inhibits cell proliferation. J. Biol. Chem. 287, 5588-5599 (2012).
5. Wakeman, T. P., Wang, Q., Feng, J. & Wang, X. F. Bat3 facilitates H3K79 dimethylation by DOT1L and promotes DNA damage-induced 53BP1 foci at G1/G2 cell-cycle phases. EMBO J. 31, 2169-2181 (2012).
6. Okada, Y. et al. hDOT1L links histone methylation to leukemogenesis. Cell 121, 167-178 (2005).
7. Bernt, K. M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66-78 (2011).
8. Chang, M. J. et al. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res. 70, 10234-10242 (2010).
9. Daigle, S. R. et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53-65 (2011).
10. Zhang, L. et al. Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer. Oncotarget 15, 10665-10677 (2014).
11. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008).
12. Scheel, C. & Weinberg, R. A. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin. Cancer Biol. 22, 396-403 (2012).
13. Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420-1428 (2009).
14. Gupta, P. B., Chaffer, C. L. & Weinberg, R. A. Cancer stem cells: mirage or reality? Nat.Med. 15, 1010-1012 (2009).
15. DiMeo, T. A. et al. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 69, 5364-5373 (2009).
16. Liu, S. & Wicha, M. S. Targeting breast cancer stem cells. J. Clin. Oncol. 28, 4006-4012 (2010).
17. Yang, M. H. et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat. Cell Biol. 12, 982-992 (2010).
18. Cho, K. B., Cho, M. K., Lee, W. Y. & Kang, K. W. Overexpression of c-myc induces epithelial mesenchymal transition in mammary epithelial cells. Cancer Lett. 293, 230-239 (2010).
19. Amatangelo, M. D., Goodyear, S., Varma, D. & Stearns, M. E. c-Myc expression and MEK1-induced Erk2 nuclear localization are required for TGF-beta induced epithelial-mesenchymal transition and invasion in prostate cancer. Carcinogenesis 33, 1965-1975 (2012).
20. Guo, W. et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148, 1015-1028 (2012).
21. Wellner, U. et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 11, 1487-1495 (2009).
22. Dong, C. et al. G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J. Clin. Invest. 122, 1469-1486 (2012).
23. Yang, F. et al. SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. EMBO J. 31, 110-123 (2012).
24. Onder, T. T. et al. Chromatin-modifying enzymes as modulators of reprogramming. Nature 483, 598-602 (2012).
25. Hoenerhoff, M. J. et al. BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases. Oncogene 28, 3022-3032 (2009).
26. Yu, M. et al. A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression. Genes Dev. 23, 1737-1742 (2009).
27. Smith, A. P. et al. A positive role for Myc in TGFbeta-induced Snail transcription and epithelial-to-mesenchymal transition. Oncogene 28, 422-430 (2009).
28. Guccione, E. et al. Myc-binding-site recognition in the human genome is determined by chromatin context. Nat. Cell Biol. 8, 764-770 (2006).
29. Kenneth, N. S. et al. TRRAP and GCN5 are used by c-Myc to activate RNA polymerase III transcription. Proc. Natl Acad. Sci. USA 104, 14917-14922 (2007).
30. Bedford, D. C., Kasper, L. H., Fukuyama, T. & Brindle, P. K. Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases. Epigenetics 5, 9-15 (2010).
31. Vervoorts, J. et al. Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO Rep. 4, 484-490 (2003).
32. Brenner, C. et al. Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J. 24, 336-346 (2005).
33. Kurland, J. F. & Tansey, W. P. Myc-mediated transcriptional repression by recruitment of histone deacetylase. Cancer Res. 68, 3624-3629 (2008).
34. Yang, L. et al. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 500, 598-602 (2013).
35. Mueller, D. et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 110, 4445-4454 (2007).
36. Krivtsov, A. V. et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14, 355-368 (2008).
37. Okada, Y. et al. Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. Nat. Cell Biol. 8, 1017-1024 (2006).
38. Daigle, S. R. et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122, 1017-1025 (2013).
39. Lee, J. Y. et al. Loss of the polycomb protein Mel-18 enhances the epithelialmesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer. Oncogene 33, 1325-1354 (2013).